Other Products

AstraZeneca’s (AZN) Other Products segment includes products related to infections treatment, neuroscience, and gastrointestinal drugs. Some of the key drugs in this segment include Nexium, Synagis, Seroquel XR, Movantik, and Losec.

The segment’s revenue fell 12% at constant exchange rates to $998 million in 1Q17. Let’s take a look at some of its key products and their performances.

How AstraZeneca’s Other Products Segment Performed in 1Q17

Nexium

Nexium, a gastrointestinal medicine for the treatment of acid-related disorders, reported a 1% rise in revenue at constant exchange rates in 1Q17. The drug reported revenue of $461 million following strong demand in US and European markets, offset by lower sales in emerging markets and the rest of the world. Its revenue is expected to fall in the coming quarters due to its exposure to generic competition in various markets.

Synagis

Synagis is used for the prevention of lung infections and infections related to breathing tubes in infants and children. Synagis’s revenue fell 6% at constant exchange rates to $230 million in 1Q17 due to lower sales in both US and the European markets.

Seroquel XR

Seroquel XR, a neuroscience medicine for the treatment of schizophrenia, reported a revenue fall of 67% at constant exchange rates to $67 million in 1Q17. This revenue fall was driven by lower sales in US, European, and emerging markets, partially offset by growth in the rest of the world.

Movantik

Movantik, a drug used for the treatment of opioid-induced constipation, reported a rise of 76% at constant exchange rates to $30 million in 1Q17 revenue. This strong performance was driven by increased demand in US markets.

To divest risk, investors can consider ETFs such as the Vanguard FTSE All-World ex-US ETF (VEU), which holds ~0.5% of its total assets in AstraZeneca. VEU also holds 1.2% of its total assets in Novartis (NVS), 0.6% in Sanofi (SNY), and 0.5% in Novo Nordisk (NVO).

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.71.127